Top-News
Gesundheitswesen Belgien

Mdxhealth SA News

Aktie
WKN:  A3E19Y ISIN:  BE0974461940 US-Symbol:  MDXH
3,09 $
+0,73 $
+30,93%
02.04.24 17:39:25
Handeln Depot/Watchlist
Aktienanzahl *
4,98 Mio.
Marktkapitalisierung *
12,33 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 15.11.2023

Mdxhealth SA News

25.04.18 - DGAP
MDxHealth (MDXH-BR): Back on track in Q1
goetzpartners securities Limited MDxHealth (MDXH-BR): Back on track in Q1 25-Apr-2018 / 11:09 GMT/BST
28.12.17 - GlobeNewswire
MDxHealth (R): MDxHealth Announces Lowering of 2017 Guidance
MDxHealth (R): MDxHealth Announces Lowering of 2017 Guidance HERSTAL, BELGIUM and IRVINE, CA - December 28, 2017 - MDxHealth SA (Euronext: MDXH.BR, "MDxHealth", or ...
19.10.16 - GlobeNewswire
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland Further broadens reach of SelectMDx(TM) for Prostate Cancer in ...
25.08.11 - Hugin
MDxHealth Reports 2011 Half-Year Results
IRVINE, CA, and LIEGE, BELGIUM - August 25, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, ...
18.08.11 - Hugin
MDxHealth establishes US CLIA laboratory in Irvine, CA, and makes key hires to expand US team
DURHAM, NC, and LIEGE, BELGIUM - August 18, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, ...
03.08.11 - Hugin
MDxHealth's biomarker part of large pivotal colon cancer trial initiated by Exact Sciences
DURHAM, NC, and LIEGE, BELGIUM - August 3, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, ...
11.07.11 - Hugin
MDxHealth's MGMT Test Shown to Be Only Prognostic Factor in Journal of Clinical Oncology Report on Newly Diagnosed Brain Cancer Patients
DURHAM, NC, and LIEGE, BELGIUM - July 11, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, ...
09.06.11 - Hugin
MDxHealth and Merck KGaA extend Agreement for use of MGMT Assay in Brain Cancer Clinical Trials
DURHAM, NC, and LIEGE, BELGIUM - June 9th, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, ...
06.06.11 - Hugin
MDxHealth's MGMT Test Identifies Brain Cancer Patients Likely to Live Longer on Temozolomide Treatment - Phase III Data Presented at ASCO
DURHAM, NC, and LIEGE, BELGIUM - June 6, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, ...
31.05.11 - Hugin
MDxHealth's Methylation Based Companion Diagnostics Enables Better Personalized Treatment in Brain Cancer
Data to be Presented at ASCO from RTOG 0525 International Phase III Trial of Temozolomide DURHAM, NC, and LIEGE, BELGIUM - May 31, 2011 - MDxHealth SA (NYSE Euronext ...
26.01.11 - Hugin
MDxHealth Biomarkers Used in Successful Testing of Predictive Biosciences' Bladder Cancer Assay
Data Presented at GTCbio's Oncology Biomarkers Conference DURHAM, NC, and LIEGE, BELGIUM - January 26, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading ...
10.01.11 - Hugin
MDxHealth Licensee Exact Sciences Confirms Use of Biomarker and Methylation Technology in its Advanced Colon Cancer Test
DURHAM, NC, and LIEGE, BELGIUM - January 10, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer ...
21.12.10 - Hugin
MDxHealth Expands Its Companion Diagnostics Capabilities
DURHAM, NC, and LIEGE, BELGIUM- December 21, 2010 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer ...
15.12.10 - Hugin
MDxHealth Amends Existing Methylation Biomarker Agreement with Veridex, LLC
Partnering of Cancer Screening Applications Supports MDxHealth's New Strategy DURHAM, NC, and LIEGE, BELGIUM - December 15, 2010 - MDxHealth SA (NYSE Euronext ...
29.11.10 - Hugin
MDxHealth Licenses Methylation Technology to Takara Bio Inc. for Scientific Research Market
DURHAM, NC, and LIEGE, BELGIUM - November 29, 2010 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer ...
22.11.10 - Hugin
MDxHealth Licenses Biomarkers for Bladder Cancer to Predictive Biosciences
DURHAM, NC, LIEGE, BELGIUM and LEXINGTON, MA - November 22nd, 2010 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of ...
04.11.10 - Hugin
MDxHealth Provides Third Quarter 2010 Business Update
DURHAM, NC, and LIEGE, BELGIUM - November 4, 2010 - MDxHealth SA (NYSE Euronext Brussels & Amsterdam: MDXH), a leading molecular diagnostics company focused on ...
06.10.10 - Hugin
OncoMethylome Sciences Changes its Name to MDxHealth
DURHAM, NC, and LIEGE, BELGIUM - October 6, 2010 - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) today announced that its ...
23.09.10 - Hugin
OncoMethylome Sciences Signs Agreement for the Potential use of its technology platform in GlaxoSmithKline Biologicals Immunotherapy Development Program
DURHAM, the United States, and LIEGE, BELGIUM - September 23rd, 2010 - OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA), a leading ...
26.08.10 - Hugin
OncoMethylome Sciences Reports 2010 Half-Year Results and Announces New Strategy
DURHAM, NC, and LIEGE, BELGIUM - August 26, 2010 - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA), a leading molecular diagnostics ...

Newssuche

Videos

newspaper
30.04.24 +12,97%
Technical Trading: Sojabohnen Long bis Juli
Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »